In this issue of Blood, Pan et al highlight their approach toward dual-antigen chimeric antigen receptor (CAR) T-cell targeting in an effort to reduce the risk of immune escape in pediatric B-cell acute lymphoblastic leukemia (B-ALL). They demonstrate the feasibility of sequentially administering CD19 CAR T cells followed by CD22 CAR T cells alongside the safety, toxicity, and efficacy of such a model. Their observation suggests that sequential CAR T-cell targeting strategies may be safe and effective and provides proof-of-concept of a potential strategy that may allow for dual-antigen CAR T-cell targeting.

中文翻译：

---

一二拳（CAR T 细胞）

在本期血液中，Pan 等人强调了他们针对双抗原嵌合抗原受体 (CAR) T 细胞的方法，以努力降低小儿 B 细胞急性淋巴细胞白血病 (B-ALL) 的免疫逃逸风险。他们证明了依次施用 CD19 CAR T 细胞和 CD22 CAR T 细胞以及这种模型的安全性、毒性和有效性的可行性。他们的观察表明，顺序 CAR T 细胞靶向策略可能是安全有效的，并为可能允许双抗原 CAR T 细胞靶向的潜在策略提供了概念验证。